19 results about "Heart contractility" patented technology

A system for application of neurostimulation includes an outer sheath, an elongate inner member in the outer sheath and movable relative to the outer sheath. The inner lumen has a distal end. An expandable member is coupled to the distal end of the inner member and is in the outer sheath. The expandable member is self-expanding upon from a compressed state in the outer sheath to an expanded state out of the outer sheath. The expandable member includes a distal portion including a plurality of wires woven together and a proximal portion including the plurality of wires extending parallel to a longitudinal axis. The system includes a plurality of electrode assemblies outward of the expandable member and circumferentially spaced around the expandable member. Each electrode assembly is coupled to two of the wires extending parallel to the longitudinal axis. Each electrode assembly includes a plurality of longitudinally-spaced electrodes.

Methods, apparatus, and systems are provided to control contraction of the heart. At least one sensing element receives signals indicating electrical activity of sinus rhythm of the heart. Based on the received signals, the progress of contraction of the heart is determined. Based on the progress of contraction, the chamber of the heart may then be stimulated at a plurality of locations. In another embodiment, a plurality of electrodes are implanted in the left ventricle to stimulate at multiple locations in the left ventricle for the purpose of improving hemodynamic performance and increasing cardiac output in a patient who is suffering from congestive heart failure.

1. A method for selecting a patient for cardiac contractile control therapy, the method comprising: selecting a patient who meets criteria for cardiac resynchronization therapy (CRT); detecting potential difficulties in effectively providing CRT to the patient; and determining that the patient can benefit from cardiac contractile control therapy despite the potential difficulties.

The disclosure relates to a method (100) for notifying a clotting event in an arterial line (1) of a human being (2), to a corresponding system, computer program product and data carrier signal. The method (100) comprises providing (110) a hemodynamic signal indicative of an arterial blood pressure waveform (10) in the arterial line (1); determining (120) a hemodynamic contraction parameter related to a contraction of the heart based on the hemodynamic signal; determining (130) a hemodynamic relaxation parameter related to a relaxation of the heart based on the hemodynamic signal; determining (140) a clotting event in the arterial line (1) in case the hemodynamic contraction parameter indicates a decrease of contractility and the hemodynamic relaxation parameter indicates an increase of contractility, and providing (150) a signal notifying of the determined clotting event.

A prosthetic heart valve has a frame and a valvular structure coupled thereto. The valvular structure has multiple leaflets, with paired tabs from the leaflets forming commissure tab assemblies that couple the valvular structure to the frame. The frame is tapered with its inflow end diameter being smaller than its outflow end diameter. The valvular structure is constructed such that a flow channel formed by the leaflets is also tapered, with the inlet end cross-section being smaller than the outlet end cross-section. The commissure tab assemblies are attached to the frame with leaflet bending axes at or adjacent to the radially-inner surface of the frame. During systole, separation of blood flow induced by the tapered geometry of the flow channel generates an annular back flow region adjacent to the inner surface of the valve at the outflow end, which prevents the free edge of the leaflets from contacting the frame.

A method of selecting a combination of electrodes for use in neurostimulation includes testing combinations of electrodes in an electrode array to identify an atrial capture. The atrial capture is indicated by at least one effect on an atrium. The method includes excluding electrodes with the atrial capture to result in remaining electrodes of the electrode array, testing combinations of the remaining electrodes of the electrode array for effect on cardiac contractility and / or relaxation, and selecting a combination of electrodes from the remaining electrodes. The selected combination has both a desired effect on cardiac contractility and / or relaxation and does not have an undesired side effect.

This invention relates to the fields of medical device technology and signal processing algorithm technology. Specifically, it relates to an in vitro cardiac contractility dynamic enhancement system and method based on R-wave peak dual-modal sensing. The problem addressed by this invention is the technical issues of poor safety, high oxygen consumption, insufficient precision, and lack of automated closed-loop control in isolated cardiac mechanical perfusion methods. To solve these problems, this invention provides an in vitro cardiac contractility dynamic enhancement method based on R-wave peak dual-modal sensing, comprising: obtaining an initial threshold and an initial R-wave template library based on real-time cardiac physiological signals within an initial target time period; obtaining the true R-wave peak based on waveform verification of candidate R-wave peaks within the target time period and the initial threshold; calculating the stimulation delay based on species-preset parameters and real-time cardiac physiological signals; and selecting the stimulation mode and adjusting the energy parameters based on changes in the real-time cardiac physiological signals.

1. The name of the design product: sphygmomanometer (XB-12). 2. The use of the design product: monitoring the pressure value generated by blood to the blood vessel wall when the heart contracts and relaxes. 3. The design points of the design product: in the overall shape. 4. The picture or photo that best indicates the design points: perspective view.

A cardiac therapy device includes a stimulation circuit configured to generate a non-excitatory electrical signal that improves a condition of heart failure in a human patient when the non-excitatory electrical signal is applied to ventricular tissue during a ventricular refractory period of the ventricular tissue; an atrial arrhythmia detection circuit; and a decision circuit that controls the stimulation circuit to deliver the signal when the atrial arrhythmia detection circuit detects an atrial arrhythmia.

The application provides a left ventricular implant and a left ventricular repair system. The left ventricular implant comprises a filling member arranged at a proximal end and a support member arranged at a distal end for supporting the filling member. The filling member comprises a filling body and a stent arranged in the filling body. When the heart contracts, the filling body and the stent are extruded, the stent is deformed, and the filling body is driven to move towards the proximal end. The unique stent structure cooperates to drive the filling body to move only towards the proximal end, and the movement direction is the same as the ejection direction, so that the proximal end of the filling body generates an additional force along the vertical axis direction to the blood flow ejected from the left ventricle to the aorta. While achieving the controlled movement direction of the proximal end of the filling body, the left ventricular pressure can be further increased. Therefore, the heart pumping function is enhanced, the physiological function of the diseased heart is improved, and sufficient blood flow is provided to meet the needs of the body.

The invention relates to a self-adaptive control artificial heart valve testing device. The testing device comprises a pulsation generation module used for generating pulsation fluid simulating systole and diastole of the heart; the sensing feedback system is used for carrying out data acquisition on the pulsating fluid and feeding back the acquired fluid data to the control system; the control system is used for adaptively adjusting working state parameters of the pulsation generation module, the liquid volume execution unit and the liquid resistance execution unit according to the fluid data so as to realize pulsating flow in a near physiological state; and the valve loading module is used for installing a to-be-tested heart valve prosthesis, so that the heart valve prosthesis can be tested by utilizing pulsating fluid in a near-physiological state, and a testing device which can realize stable and continuous pulsating flow close to a real physiological state in vitro and has self-adaptive regulation and control capability is realized. The method is of great significance to simulation of pathological states of different patients, improvement of data consistency among laboratories and acceleration of research, development and manufacturing of artificial heart valves.

A prosthetic valve for treating blood regurgitation through a native heart valve can include a body including an inlet portion and an outlet portion having a first leaflet and a second leaflet, and the body defining a flow passage having an inlet within the inlet portion, a first outlet within the first leaflet, and a second outlet within the second leaflet; and a flow control device disposed in the flow passage within the inlet portion and a clip connector coupled to the body. The prosthetic valve is configured to be disposed in a native valve of a heart that has been pinched to create a first flow control portion and a second flow control portion, with the inlet disposed in a heart atrium and the first outlet and the second outlet disposed in a heart ventricle, wherein the leaflets are configured to be disposed in the flow control portions in substantially sealing relation with the first leaflet and the second leaflet. The prosthetic valve is further configured to allow blood to flow from the atrium to the ventricle through the flow passage and substantially prevent blood from flowing from the ventricle to the atrium through the flow passage or between the body and the leaflets during a contraction of the heart. The clip connector is configured to selectively couple to a clip and resist displacement of the body toward the atrium during the contraction.

The invention provides an integrated valved blood vessel construction and hemodynamic performance optimization method, the integrated valved blood vessel comprises a blood vessel pipeline and a valve, the valve comprises a plurality of valve leaflets, and the number of the valve leaflets is greater than or equal to four; a guide piece is arranged in the blood vessel pipeline, a guide groove is formed in the valve leaflet, and the guide piece is inserted into the guide groove and can slide in the guide groove; when the heart contracts, the side edges of every two adjacent valve leaflets can be far away from each other under the action of blood flow pressure, so that the valve is in an open state; when the heart is relaxed, under the action of the dead weight and the elasticity of the valve leaflets, the side edges of every two adjacent valve leaflets can be attached, and the valve is in a closed state. By increasing the number of the valve leaflets, the valve structure is firmer and can bear higher hydrodynamic load, so that the durability is improved; by arranging the guide piece and the guide groove, when the valve is opened and closed, the valve leaflet is forced to move along a preset track, the valve can be tightly closed after long-time use, and the service life of the valve is prolonged.

Methods and associated devices for enhancing peak VO2 in patients are disclosed.SOLUTION: A method of enhancing peak VO2, comprising: selecting a subject having an impaired peak VO2 and estimated to have a likelihood of improving peak VO2; and applying cardiac contractility modulation stimulation to the subject. The method includes detecting a ventricular contraction using one or more leads placed in a ventricle of the patient and applying a cardiac contractility modulating stimulus to the ventricle of the patient after a delay from a time of the detection.SELECTED DRAWING: Figure 1B

This application provides a self-expanding occlusion device for implantation between heart valves. The device includes a self-expanding body having: an elastic surface extending circumferentially along axis A to form a hollow cavity; a first port located proximal to the elastic surface and circumferentially surrounding axis A; and a second port located distal to the elastic surface and circumferentially surrounding axis A. The first port, the cavity, and the second port are interconnected. The second port is larger than the first port. This self-expanding occlusion device cleverly integrates its structure with the flow of blood during cardiac contraction and relaxation. For patients with valvular regurgitation, the self-expanding occlusion device can effectively resolve blood regurgitation in conjunction with the native valve during systole, and reduce obstruction of blood flow during diastole.

1. The name of the design product: sphygmomanometer (XB-11). 2. The use of the design product: monitoring the pressure value generated by blood to the blood vessel wall when the heart contracts and relaxes. 3. The design points of the design product: in the overall shape. 4. The picture or photo that best indicates the design points: perspective view.

The invention belongs to the technical field of medical instruments, and particularly relates to an ascending aorta covered stent with biomechanical property, which comprises a support skeleton, the inner side and the outer side of the support skeleton are both covered with films, the support skeleton is formed by spirally winding functional metal wires, the functional metal wires are formed by spirally winding composite wires, and the functional metal wires are wound by the composite wires. And the composite filament is formed by weaving a plurality of strands of filaments. In terms of overall performance, the large vessel covered stent can be highly synchronized with radial expansion / retraction, circumferential stretching, longitudinal displacement and slight torsion generated by the ascending aorta in the cardiac contraction and diastole period, and therefore natural physiological movement of the aorta is effectively simulated.

Disclosed are methods and agents for treating heart failure. More particularly, the present disclosure relates to the use of CD14 antagonist antigen-binding molecules for treating heart failure, including alleviating, reducing or reversing adverse cardiac structural remodeling, improving cardiac contractile function, improving ejection fraction (e.g., left ventricular ejection fraction), left ventricular end-systolic volume, left ventricular end- diastolic volume, left ventricular akinesia, left ventricular dilatation, and / or left ventricular hypertrophy, reducing dyspnea, improving congestion score and / or patient perception of their health status and / or reducing neutrophil / lymphocyte ratio.

Methods and apparatus are provided for estimating a measure of cardiac contractility based on a set of features determined from a set of signals associated with a mechanical loop support device. The method includes determining, using a computer processor, a set of features based at least in part on the set of signals; providing the set of features as inputs to a machine learning model, the machine learning model trained to output a measure of cardiac contractility; and performing an action based at least in part on the measure of cardiac contractility output by the machine learning model.